m+Medelevator.RU
← Поиск публикаций
Biosensors & bioelectronics · 2021

Confining copper nanoclusters on exfoliation-free 2D boehmite nanosheets: Fabrication of ultra-sensitive sensing platform for α-glucosidase activity monitoring and natural anti-diabetes drug screening.

СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Chen Sihan, Li Zheng, Li Wenjun, Huang Zhenzhen, Jia Qiong

Аннотация

α-Glucosidase (α-Glu) and its inhibitors play critical roles in diabetes therapy. Herein, a simple and ultra-sensitive fluorescence sensing approach was fabricated for α-Glu activity monitoring and natural inhibitor screening by electrostatically confining negatively charged glutathione-capped copper nanoclusters (GSH-CuNCs) on exfoliation-free and positively charged 2D boehmite (Boe) nanosheets. Boe significantly improved the fluorescence emission/stability of GSH-CuNCs and simultaneously led to an obvious blue-shift of the excitation peak of CuNCs from 365 nm to 330 nm. As a result, the fluorescence emission of Boe@GSH-CuNCs was efficiently quenched by 4-nitrophenyl-α-D-glucopyranoside (PNPG) with a maximum absorbance peak (λmax) at 310 nm via inner filter effect, and sequentially recovered by α-Glu through the hydrolysis of PNPG to p-nitrophenol (λmax = 410 nm). Accordingly, an ultra-sensitive fluorescence assay for the determination of α-Glu activity was proposed by using Boe@GSH-CuNCs as fluorescence probes. The detection limit of 0.43 U/L was achieved, which was lower than most of other α-Glu activity assays. Furthermore, this method was capable of screening α-Glu inhibitors originated from actinomycetes, peanut, sophora flower, celery, and orange as potential anti-diabetes drugs. Taken together, this work provided a promising strategy for clinical treatment of diabetes and discovery of anti-diabetes drugs.

Предметные рубрики MeSH

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты